<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 24 Feb 2021 11:20:18 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>君实生物申报首个双抗：PD-1/TGFβ</title><link>https://mp.weixin.qq.com/s/_nXR2PK_oZwJAowJiLuQhw</link><description></description><content:encoded><![CDATA[君实生物申报首个双抗：PD-1/TGFβ]]></content:encoded><pubDate>Wed, 24 Feb 2021 08:23:03 +0800</pubDate></item><item><title>君实生物申报EGFR-exon20小分子抑制剂</title><link>https://mp.weixin.qq.com/s/pVWzeLDrSn4pgSc3Uhc7mA</link><description></description><content:encoded><![CDATA[君实生物申报EGFR-exon20小分子抑制剂]]></content:encoded><pubDate>Mon, 22 Feb 2021 16:14:15 +0800</pubDate></item><item><title>100款已上市抗体药物氨基酸序列</title><link>https://mp.weixin.qq.com/s/zxl0uNYyOF_qKiG_G3TleA</link><description></description><content:encoded><![CDATA[100款已上市抗体药物氨基酸序列]]></content:encoded><pubDate>Sun, 21 Feb 2021 21:28:19 +0800</pubDate></item><item><title>100款已上市抗体药物的免疫原性</title><link>https://mp.weixin.qq.com/s/fiSEr-INBnvToOsk_Tkw0w</link><description></description><content:encoded><![CDATA[100款已上市抗体药物的免疫原性]]></content:encoded><pubDate>Sun, 21 Feb 2021 21:28:19 +0800</pubDate></item><item><title>100款已上市抗体药物的制剂处方</title><link>https://mp.weixin.qq.com/s/SWb_HKP61b6RZEUQ5V9p_Q</link><description></description><content:encoded><![CDATA[100款已上市抗体药物的制剂处方]]></content:encoded><pubDate>Sun, 21 Feb 2021 21:28:19 +0800</pubDate></item><item><title>VEGF治疗眼病：罗氏的三重护城河</title><link>https://mp.weixin.qq.com/s/zMR7UzBySTYBfCjeE4VVAQ</link><description></description><content:encoded><![CDATA[VEGF治疗眼病：罗氏的三重护城河]]></content:encoded><pubDate>Sat, 20 Feb 2021 14:16:17 +0800</pubDate></item><item><title>多特异性纳米抗体：或成对抗新冠变异的有效武器</title><link>https://mp.weixin.qq.com/s/Osl0PQ2_cGfYcMg1XOJxAw</link><description></description><content:encoded><![CDATA[多特异性纳米抗体：或成对抗新冠变异的有效武器]]></content:encoded><pubDate>Fri, 19 Feb 2021 09:27:29 +0800</pubDate></item><item><title>成立6个月，联拓生物启动FGFR抑制剂三期临床</title><link>https://mp.weixin.qq.com/s/Q2ne2z7Bi8gdtWjs7v74Sg</link><description></description><content:encoded><![CDATA[成立6个月，联拓生物启动FGFR抑制剂三期临床]]></content:encoded><pubDate>Fri, 19 Feb 2021 09:27:29 +0800</pubDate></item><item><title>国内首个：迈威生物申报ST2抗体</title><link>https://mp.weixin.qq.com/s/fddboQe5XXcv0p4qwCDRqw</link><description></description><content:encoded><![CDATA[国内首个：迈威生物申报ST2抗体]]></content:encoded><pubDate>Fri, 19 Feb 2021 09:27:29 +0800</pubDate></item><item><title>David Baker成功实现跨膜TMB的从头设计</title><link>https://mp.weixin.qq.com/s/i3saMA1qCCfPA2u-SswR9A</link><description></description><content:encoded><![CDATA[David Baker成功实现跨膜TMB的从头设计]]></content:encoded><pubDate>Fri, 19 Feb 2021 09:27:29 +0800</pubDate></item><item><title>全人源抗体</title><link>https://mp.weixin.qq.com/s/DXGT00Exm8PNDsfg39pcrg</link><description></description><content:encoded><![CDATA[全人源抗体]]></content:encoded><pubDate>Thu, 18 Feb 2021 09:08:33 +0800</pubDate></item><item><title>豪森药业1.32亿美元引进抗真菌感染药物</title><link>https://mp.weixin.qq.com/s/NHZQyII9835qPZY6HoDQNA</link><description></description><content:encoded><![CDATA[豪森药业1.32亿美元引进抗真菌感染药物]]></content:encoded><pubDate>Thu, 18 Feb 2021 09:08:33 +0800</pubDate></item><item><title>百济神州1.21亿美元引进TNFR2抗体</title><link>https://mp.weixin.qq.com/s/qSPj13mwcXnuO6qIiAcmLw</link><description></description><content:encoded><![CDATA[百济神州1.21亿美元引进TNFR2抗体]]></content:encoded><pubDate>Thu, 18 Feb 2021 09:08:33 +0800</pubDate></item><item><title>WHO批准阿斯利康新冠疫苗</title><link>https://mp.weixin.qq.com/s/gTlk4ikOP40W8uAOoPjm1w</link><description></description><content:encoded><![CDATA[WHO批准阿斯利康新冠疫苗]]></content:encoded><pubDate>Wed, 17 Feb 2021 00:35:14 +0800</pubDate></item><item><title>Bluebird基因疗法患者出现1例血液瘤副作用，股价暴跌30%</title><link>https://mp.weixin.qq.com/s/h_68nxO5zWojvIbE2TJnCg</link><description></description><content:encoded><![CDATA[Bluebird基因疗法患者出现1例血液瘤副作用，股价暴跌30%]]></content:encoded><pubDate>Wed, 17 Feb 2021 00:35:14 +0800</pubDate></item><item><title>O药、K药大战一线肾癌</title><link>https://mp.weixin.qq.com/s/rL5byhCPNyWzKtiyvTs1zw</link><description></description><content:encoded><![CDATA[O药、K药大战一线肾癌]]></content:encoded><pubDate>Sun, 14 Feb 2021 11:59:15 +0800</pubDate></item><item><title>FDA批准第100款抗体药</title><link>https://mp.weixin.qq.com/s/WI7Kk-3pbMKyoVi1967-oQ</link><description></description><content:encoded><![CDATA[FDA批准第100款抗体药]]></content:encoded><pubDate>Sat, 13 Feb 2021 10:07:33 +0800</pubDate></item><item><title>K药头对头：翰思生物PD-1启动非小细胞肺癌2/3期临床</title><link>https://mp.weixin.qq.com/s/WhX4qcDvH00JDRh84jiNVw</link><description></description><content:encoded><![CDATA[K药头对头：翰思生物PD-1启动非小细胞肺癌2/3期临床]]></content:encoded><pubDate>Thu, 11 Feb 2021 23:40:46 +0800</pubDate></item><item><title>创响生物IL-17类抗体申报临床</title><link>https://mp.weixin.qq.com/s/USwtIP2fVGteIfz2mbHbLQ</link><description></description><content:encoded><![CDATA[创响生物IL-17类抗体申报临床]]></content:encoded><pubDate>Thu, 11 Feb 2021 23:40:46 +0800</pubDate></item></channel></rss>